News & Videos - FAGRON - English

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 7 Jan 2025 – 7AM CET Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil Fagron, the leading global player in pharmaceutical compounding is pleased to announce the signing of two strategic acquisitions: CareFirst Specialty Pharmacy in North America and Injeplast in Brazil. These acquisitions underscore Fagron’s commitment to expanding across our key markets...

Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Following the FDA’s routine inspection at Fagron’s Wichita facility conducted in June 2024, the Company received a warning letter from the FDA (Warning Letter) on December 19, 2024. The Warning Letter requires Fagron to enhance processes for investigating discrepancies, and validations of future...

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2024. Key Highlights Continued topline momentum with 12.1% reported revenue growth (15.7% at CER) and 12.2% organic growth...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 August 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 26 August 2024 through 30 August 2024, Fagron purchased 37,000 of its own shares at an average price of € 18.99 per share corresponding to a total amount of € 1,357,476.41. These purchases are part of the share buy-back program of up to 150,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 23 August 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 19 August 2024 through 23 August 2024, Fagron purchased 34,500 of its owns shares at an average price of € 18.99 per share corresponding to a total amount of € 655,081.09. These purchases are part of the share buy-back program of up to 150,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2024. Key Highlights Strong topline performance with 15.5% reported revenue growth (15.3% at Constant Exchange Rates (CER)) and...

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2024. Key Highlights Revenue growth accelerated to 15.3% reported growth (14.9% at CER) resulting in €209.2 million, supported by all regions Organic growth at CER...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 19 March 2024 – 6PM CET Disclosure notification from Mawer Investment Management Ltd. On 18 March 2024, Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Mawer Investment Management Ltd. that its shareholding crossed the 5% disclosure threshold as the result of the acquisition of voting securities or voting rights on 15 March...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 14 March 2024 – 6:30 PM CET Fagron publishes annual report 2023 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2023. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 13 May 2024. The annual report is available in the official Dutch version and in English...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 19 September 2023 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last period, from 18 September 2023 through 19 September 2023, Fagron purchased 17,266 of its owns shares at an average price of €16.12 per share corresponding to a total amount of €277,612.81. A total of 138,372 Fagron shares have been repurchased under the buy-back program at an...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 September 2023 – 6PM CET Progress share buy-back program Fagron In the period from 4 September 2023 through 8 September 2023, Fagron purchased 16,146 of its owns shares at an average price of €16.60 per share corresponding to a total amount of €268,005.84. These purchases are part of the share buy-back program of up to 138,372 Fagron shares to fulfill Fagron’s obligations under its long term incentive scheme, which...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 May 2023 – 7 PM CET Fagron shareholders approve majority voting items Today, Fagron, the leading global player in pharmaceutical compounding, held its annual general meeting of shareholders. The meeting approved the voting items, with the exemption of the proposal to approve the accelerated vesting in case of a public offer on or a change of control over Fagron as provided for in the Performance Share Plan (agenda item...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 3 May 2023 – 8:00 AM CET Fagron increases share capital through exercise subscription rights Fagron, the leading global player in pharmaceutical compounding, announces that as a result of the exercise of subscription rights, 236,250 new shares have been issued on 2 May 2023. These newly issued shares are entitled to dividend as of financial year 2022. In accordance with the Belgian transparency legislation, Fagron notes that...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2023 – 6:30 PM CET Disclosure of notification received from FMR LLC Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from FMR LLC. Notification of FMR LLC On 16 March 2023, Fagron received a notification that the shareholding of FMR LLC crossed the disclosure threshold of 5% on 15 March 2023 as the result of the disposal of...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2023 – 8:00 AM CET Fagron publishes annual report 2022 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2022. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders early May. The annual report is available in the official Dutch version and in English translation on...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 September 2022 – 8 AM CET Fagron commits to set science-based emission reduction targets Fagron, the leading global player in pharmaceutical compounding, announces that it has committed to set science-based emission reduction targets and have these validated by the Science Based Targets initiative (SBTi) to meet the goals of the Paris Agreement of limiting global warming to 1.5°C. Rafael Padilla, CEO of Fagron commented...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 August 2022 – 8AM CET Disclosure of received notification from The Goldman Sachs Group, Inc. and NN Group N.V. Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies (the Law ), Fagron received notifications from The Goldman Sachs Group, Inc. and NN Group N.V. Notification from The Goldman Sachs Group, Inc. On 23 August 2022, Fagron received a notification that the...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 13 June 2022 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 32,500 new shares have been issued on 10 June 2022. These newly issued shares are entitled to dividend as of the 2022 financial year. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to €...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 April 2022 Fagron publishes agenda 2022 annual general meeting and extraordinary general meeting The Board of Directors of Fagron NV (Fagron) invites the holders of shares and subscription rights of Fagron to attend the annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 9 May 2022. Both meetings will be held in hybrid format. Agenda The agenda includes the discussion of the...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 15 March 2022 – 7AM CET Fagron to present medium-term strategic objectives at its Capital Markets Day Fagron, the leading global player in pharmaceutical compounding will host its Capital Markets Day today from 2PM CET. At the event, CEO Rafael Padilla and CFO Karin de Jong will be joined by other members of the management team to provide an update on Fagron’s strategic plan and growth ambitions. Fagron will outline the...